A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients

Oncology (Switzerland)

Volumn 88, Issue 4, 2014, Pages 208-213

  Jatoi, Aminah ^a   Radecki Breitkopf, Carmen ^b   Foster, Nathan R ^a   Block, Matthew S ^a   Grudem, Megan ^a   Wahner Hendrickson, Andrea ^a   Carlson, Rachel E ^a   Barrette, Brigitte ^c   Karlin, Nina ^d   Fields, Alan P ^e  

^a MAYO CLINIC   (United States)

^b Health Sciences Research   (United States)

^c Department of Gynecology ^*  (United States)

^d MAYO CLINIC   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Auranofin; CA 125; Gold; Ovarian cancer

Indexed keywords

AURANOFIN; CA 125 ANTIGEN; PROTEIN KINASE C IOTA; ANTIRHEUMATIC AGENT; ISOENZYME; PROTEIN KINASE C; PROTEIN KINASE C LAMBDA; TUMOR MARKER;

ARTICLE; ASYMPTOMATIC DISEASE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DIARRHEA; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEMI STRUCTURED INTERVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; AGED; ANTAGONISTS AND INHIBITORS; CANCER STAGING; DRUG ADMINISTRATION; ENZYMOLOGY; FOLLOW UP; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; AURANOFIN; CA-125 ANTIGEN; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PILOT PROJECTS; PROGNOSIS; PROTEIN KINASE C; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84926408093     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000369257     Document Type: Article

References (11)

1. Parker PJ, Justilien V, Riou P, Minch M, Fields AP: Atypical protein kinase C? as a human oncogene and therapeutic target. Biochem Pharmacol 2014; 88: 1-11.
2. Zhang L, Huang J, Yang N, et al: Integrative genomic analysis of protein kinase C family identified PKC? as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 2006; 66: 4627-4635.
3. Wang Y, Jill KS, Fields AP: PKC? maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis. Mol Cancer Res 2013; 11: 1624-1635.
4. Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, Molina JR: Phase I dose escalation study of the PKC? inhibitor aurothiomalate for advanced non-small cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs 2013; 24: 1079-1083.
5. Syrios J, Banerjee S, Kaye SB: Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets-where are we now? Anticancer Res 2014; 34: 2069-2077.
6. Hurteau JA, Brady MF, Darcy KM, et al: Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor: a Gynecological Oncology Group Study. Gynecol Oncol 2010; 119: 444-450.
7. Rustin GJ, van der Burg ME, Griffin CL, et al: Early versus delayed treatment of relapsed ovarian cancer (MRC OVO5/EORTC 55955): a randomized trial. Lancet 2010; 376: 1155-1163.
8. Itokazu M, Matsunaga T, Oshita Y: Efficacy and safety of auranofin in patients with active early rheumatoid arthritis. Clin Ther 1995; 17: 60-73.
9. Braun V, Clarke V: Using thematic analysis in psychology. Quant Res Psychol 2006; 3: 77-101.
10. Patton MQ: Qualitative Research and Evaluation Methods, ed 3. Thousand Oaks, Sage, 2002, p 688.
11. Harrison JD, Juraskova I, Anderson C, et al: Rising cancer antigen 125 level and the type and timing of treatment for recurrent ovarian cancer. Int J Gynecol Cancer 2009; 19: 1037-1046.